Remove 2019 Remove Process Improvement Remove Vaccines
article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

2 October 2019. Manufacturing Biological Medicines on Demand: Safety and Efficacy of Granulocyte Colony-Stimulating Factor in a Mouse Model of Total Body Irradiation.” “Sanofi Pumps $554M into New Vaccine Manufacturing Facility in Eastern France.” New Project: Evolutive Vaccines Facility for Sanofi.” 11 September 2019.

article thumbnail

Streamlining Postapproval Submissions Using ICH Q12 & SCDM

ISPE

Following approval of an initial marketing application, postapproval changes are needed to ensure adequate supply, mitigate supply risk, expand patient market access, optimize manufacturing processes, improve analytical methods, and comply with new regulatory expectations. Published November 2019. Published November 2019.

article thumbnail

Regulatory Landscape for Raw Materials: CMC Considerations

ISPE

During the pandemic, the pharmaceutical industry faced challenges in the production of COVID-19 therapeutics and vaccines to meet global demand, as well as mitigation of drug shortages for non-COVID-19-related products, without compromising product quality or patient safety. Published November 2019. 9 Lo Surdo, J. Cauchon, C.